NCT05023707招募中1 期
Pilot Study of the Safety and Efficacy of Anti-FLT3 Chimeric Antigen Receptor Engineered T-Cells in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Soochow University1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2021年12月31日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Number of Adverse Events
研究概览
简要总结
This is a prospective,open-label, phase1/2 study to evaluate the safety and efficacy of anti-FLT3 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of FLT3 positive relapsed or refractory acute myeloid leukemia.
详细描述
The patients will receive infusion of anti-FLT3 CAR T-cells targeting FLT3 to evaluate the safety and efficacy of anti-FLT3 CAR T-Cells in relapsed or refractory acute myeloid leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •FLT3 positive relapsed/refractory acute myeloid leukemia
- •Age 16-65 years.
- •Left ventricular ejection fractions ≥ 0.5 by echocardiography
- •Creatinine < 1.5x upper limit of normal.
- •Aspartate aminotransferase/aspartate aminotransferase ≤ 2.5x upper limit of normal
- •Total bilirubin ≤ 1.5x upper limit of normal
- •Karnofsky performance status ≥ 60
- •Expected survival time ≥ 3 months (according to investigator's judgement)
排除标准
- •Patients are pregnant or lactating
- •Uncontrolled active infection
- •Grade III/IV cardiovascular disability according to the New York Heart
- •Association Classification
- •Active hepatitis B or hepatitis C infection
- •Patients with HIV infection
- •Patients with a history of seizure
- •Patients with other contraindications considered unsuitable for participation in this study (according to investigator's judgement)
研究组 & 干预措施
CAR-T infusion
Experimental
FLT3 positive relapsed or refractory acute myeloid leukemia
干预措施: anti-FLT3 CAR-T (Biological)
结局指标
主要结局
Number of Adverse Events
时间窗: 12 months
Adverse events are evaluated with CTCAE V5.0
次要结局
- Overall response rate (ORR)(2 years)
- Event-free survival (EFS)(2 years)
- Cumulative incidence of relapse(CIR)(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of LY2951742 (Galcanezumab) in Japanese Participants With MigraineMigraineNCT02959190Eli Lilly and Company311
已完成
3 期
A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TBPulmonary TuberculosisNCT02333799Global Alliance for TB Drug Development109
已完成
2 期
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based RegimenMetastatic Colorectal CancerNCT03279289Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)170
已完成
1 期
Pilot Trial of Single Dose Ilofotase Alfa in HypophosphatasiaHypophosphatasiaNCT05890794AM-Pharma12
已完成
3 期
Japanese P III vs Voglibose and PlaceboDiabetes Mellitus, Type 2NCT00654381Boehringer Ingelheim561